NUEDEXTA: payments to doctors
Payments that named NUEDEXTA as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $7.2M
- Providers
- 25,630
- Transactions
- 106,927
- Average per transaction
- $67
The per-transaction average — $67 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 25,630 providers the average total is $282, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Avanir Pharmaceuticals, Inc. | $5,706,276 | 79.1% |
| Otsuka America Pharmaceutical, Inc. | $1,508,711 | 20.9% |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | $165 | 0.0% |